Unknown PHASE2 INTERVENTIONAL NCT00299351

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

Sponsor: Royal Marsden NHS Foundation Trust

Conditions Peripheral T Cell Lymphoma (PTCL)

Updated 4 times since 2017 Last updated: Mar 3, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00299351, this PHASE2 trial focuses on Peripheral T Cell Lymphoma (PTCL) and remains ongoing. Sponsored by Royal Marsden NHS Foundation Trust, it has been updated 4 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Royal Marsden NHS Foundation Trust

Data source: Royal Marsden NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.